Gland Pharma Q2 Review: A Deep Dive into the Numbers

Gland Pharma, one of India’s leading pharmaceutical companies, has released its Q2 FY26 results, which have been reviewed by Motilal Oswal. The brokerage firm has hiked its target price for the company post inline revenue, citing a strong growth trajectory. In this article, we will delve into the details of the review and what it means for investors.

Q2 FY26 Results: A Mixed Bag

Gland Pharma delivered in-line revenue in Q2 FY26, however, its Ebitda and PAT came in below brokerage’s expectations by 9% and 11% respectively. A lower than-expected share of milestone income and lower tech transfer/contract manufacturing organisation business in rest of world markets impacted Q2 FY26 performance.

The company’s revenue for the quarter stood at Rs , which is a increase from the same period last year. The revenue growth was driven by the increase in sales of its key products, including . However, the company’s margins were impacted due to higher raw material costs and lower other income.

Motilal Oswal’s Review: Hiking Target Price

Motilal Oswal has hiked its target price for Gland Pharma to Rs 2,310, citing a strong growth trajectory. The brokerage firm expects the company’s sales to grow at a CAGR of 13% over FY25-28, driven by the increasing capacity utilization of GLP-1 pens/cartridge for non-regulated market in the initial phase of patent expiries in these markets.

The firm has also maintained its ‘Buy’ rating on the stock, citing the company’s strong product pipeline and increasing traction in the global markets. The brokerage firm expects the company’s Ebitda and PAT to grow at a CAGR of 18% and 24% respectively over FY25-28.

What Does This Mean for Investors?

The review by Motilal Oswal is a positive sign for investors, as it indicates that the brokerage firm is bullish on the company’s growth prospects. The hiking of the target price to Rs 2,310 also suggests that the firm expects the company’s stock to perform well in the near term.

However, investors should also consider the risks associated with the company, including the intense competition in the pharmaceutical industry and the regulatory risks. Investors should also keep an eye on the company’s margins, as they have been impacted in the recent quarter.

To know more about the pharmaceutical industry and its trends, click here. For more information on stock market news, click here.

Conclusion

In conclusion, Gland Pharma’s Q2 FY26 results have been reviewed by Motilal Oswal, with the brokerage firm hiking its target price post inline revenue. The review is a positive sign for investors, as it indicates that the firm is bullish on the company’s growth prospects. However, investors should also consider the risks associated with the company and keep an eye on its margins.

For more information on investing in the stock market, click here. To know more about the Nifty and Sensex, click here.